source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-13 19:30:00
| null |
XCEL BRANDS, INC. ANNOUNCES THIRD QUARTER AND FIRST NINE MONTHS OF 2019 RESULTS.Q3 GAAP LOSS PER SHARE $0.01.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.06.Q3 REVENUE ROSE 32 PERCENT TO $10.9 MILLION.
|
XCEL BRANDS REPORTS THIRD QUARTER RESULTS
|
XELB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-12 22:30:00
| null |
XCEL BRANDS, INC. ANNOUNCED EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019. FOR THE THIRD QUARTER, THE COMPANY ANNOUNCED TOTAL REVENUE WAS USD 10.932 MILLION COMPARED TO USD 8.267 MILLION A YEAR AGO. OPERATING INCOME WAS USD 372,000 COMPARED TO USD 1.398 MILLION A YEAR AGO. NET LOSS WAS USD 95,000 COMPARED TO NET INCOME OF USD 982,000 A YEAR AGO. BASIC LOSS PER SHARE WAS USD 0.01 COMPARED TO BASIC EARNINGS PER SHARE OF USD 0.05 A YEAR AGO. FOR THE NINE MONTHS, TOTAL REVENUE WAS USD 30.371 MILLION COMPARED TO USD 25.520 MILLION A YEAR AGO. OPERATING INCOME WAS USD 4.321 MILLION COMPARED TO USD 3.896 MILLION A YEAR AGO. NET INCOME WAS USD 1.884 MILLION COMPARED TO USD 1.369 MILLION A YEAR AGO. BASIC EARNINGS PER SHARE WAS USD 0.1 COMPARED TO USD 0.07 A YEAR AGO.
|
XCEL BRANDS, INC. REPORTS EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019
|
XELB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-06 22:30:00
| null |
XCEL BRANDS, INC., Q3 2019 EARNINGS CALL, NOV 13, 2019
|
XCEL BRANDS, INC., Q3 2019 EARNINGS CALL, NOV 13, 2019
|
XELB
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-09 08:00:00
| null |
XEN1101 PHASE 3 EPILEPSY PROGRAM ONGOING IN FOCAL ONSET SEIZURES AND RECENTLY INITIATED IN PRIMARY GENERALIZED TONIC CLONIC SEIZURES
|
XENON PHARMACEUTICALS OUTLINES KEY MILESTONE OPPORTUNITIES FOR 2023
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-02 08:30:00
| null |
COMPANY PRESENTS ADDITIONAL POSITIVE DATA FROM OPEN LABEL EXTENSION OF PHASE 2B ‘X-TOLE' CLINICAL TRIAL FOR FOCAL ONSET SEIZURES
|
XENON PHARMACEUTICALS PROVIDES UPDATES ON PROPRIETARY NEUROLOGY PIPELINE PROGRAMS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES 2022)
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-07 08:30:00
| null |
BURNABY, BRITISH COLUMBIA, NOV. 07, 2022 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF ANDREA DIFABIO AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY, EFFECTIVE IMMEDIATELY. MS. DIFABIO WILL PROVIDE STRATEGIC LEADERSHIP AND OVERSIGHT OF THE PLANNING AND EXECUTION FOR XENON'S LEGAL FUNCTION ON A GLOBAL BASIS.
|
XENON PHARMACEUTICALS STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF ANDREA DIFABIO AS CHIEF LEGAL OFFICER AND CORPORATE SECRETARY
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-27 14:11:00
| null |
BURNABY, BRITISH COLUMBIA, JUNE 27, 2022 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 9,098,362 COMMON SHARES, WHICH INCLUDES 1,229,508 SHARES SOLD UPON THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES, AND PRE-FUNDED WARRANTS TO PURCHASE 327,868 COMMON SHARES. THE COMMON SHARES WERE OFFERED AT A PUBLIC OFFERING PRICE OF $30.50 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS WERE OFFERED AT A PRICE OF $30.4999 PER PRE-FUNDED WARRANT, WITH EACH PRE-FUNDED WARRANT HAVING AN EXERCISE PRICE OF $0.0001. THE AGGREGATE GROSS PROCEEDS TO XENON FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY XENON, WERE APPROXIMATELY $287.5 MILLION.
|
XENON PHARMACEUTICALS ANNOUNCES CLOSING OF $287.5 MILLION PUBLIC OFFERING INCLUDING FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-22 22:27:00
| null |
BURNABY, BRITISH COLUMBIA, JUNE 22, 2022 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 7,868,854 COMMON SHARES AND, IN LIEU OF COMMON SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 327,868 COMMON SHARES PURSUANT TO ITS EXISTING SHELF REGISTRATION STATEMENT. THE COMMON SHARES ARE BEING OFFERED AT A PUBLIC OFFERING PRICE OF $30.50 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS ARE BEING OFFERED AT A PRICE OF $30.4999 PER PRE-FUNDED WARRANT. THE GROSS PROCEEDS TO XENON FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY XENON, ARE EXPECTED TO BE APPROXIMATELY $250.0 MILLION. IN ADDITION, XENON HAS GRANTED TO THE UNDERWRITERS OF THE OFFERING AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 1,229,508 COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JUNE 27, 2022, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.
|
XENON PHARMACEUTICALS ANNOUNCES PRICING OF $250.0 MILLION PUBLIC OFFERING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-22 16:02:00
| null |
BURNABY, BRITISH COLUMBIA, JUNE 22, 2022 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ: XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON SHARES AND, IN LIEU OF COMMON SHARES TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE COMMON SHARES, PURSUANT TO ITS EXISTING SHELF REGISTRATION STATEMENT. IT IS EXPECTED THAT THE UNDERWRITERS OF THE OFFERING WILL BE GRANTED AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 15% OF COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED.
|
XENON PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-22 16:01:00
| null |
NEW XEN1101 PHASE 2B X-TOLE SUB-GROUP ANALYSIS DEMONSTRATES STATISTICALLY SIGNIFICANT EFFICACY RESULTS AT ALL DOSES AT WEEK 1, DIFFERENTIATING XEN1101 WITH RAPID ONSET TO SEIZURE REDUCTION
|
XENON PHARMACEUTICALS PROVIDES UPDATE ON ADDITIONAL POSITIVE DATA FROM THE XEN1101 PROGRAM
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-21 07:00:00
| null |
XEN1101 PHASE 3 PROGRAM FOR THE TREATMENT OF FOCAL ONSET SEIZURES TO BE INITIATED IN THE SECOND HALF OF 2022 AND NEW DRUG APPLICATION EXPECTED TO BE SUBMITTED AFTER COMPLETION OF FIRST PHASE 3 CLINICAL TRIAL (X-TOLE2) ALONG WITH THE COMPLETED PHASE 2B (X-TOLE) CLINICAL TRIAL
|
XENON PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF END-OF-PHASE 2 MEETING WITH THE FDA
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-12 08:00:00
| null |
BURNABY, BRITISH COLUMBIA, JAN. 12, 2022 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT ITS COLLABORATION TO DEVELOP TREATMENTS FOR EPILEPSY WITH NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) ACHIEVED A REGULATORY MILESTONE, WHICH HAS TRIGGERED AN AGGREGATE PAYMENT OF $15.0 MILLION TO XENON. THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED NEUROCRINE'S PROTOCOL AMENDMENT THAT EXPANDS THE STUDY POPULATION TO INCLUDE SUBJECTS AGED BETWEEN 2 AND 11 YEARS IN THE ONGOING PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF NBI-921352 IN PEDIATRIC PATIENTS WITH SCN8A DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (SCN8A-DEE).
|
XENON PHARMACEUTICALS ANNOUNCES COLLABORATION WITH NEUROCRINE BIOSCIENCES ACHIEVES $15.0 MILLION REGULATORY MILESTONE
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-10 08:30:00
| null |
BURNABY, BRITISH COLUMBIA, JAN. 10, 2022 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, TODAY OUTLINED ITS KEY MILESTONES FOR 2022.
|
XENON PHARMACEUTICALS OUTLINES KEY MILESTONE OPPORTUNITIES FOR 2022
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-03 07:00:00
| null |
TOPLINE DATA SHOWED ALL PRIMARY AND SECONDARY SEIZURE REDUCTION ENDPOINTS STATISTICALLY SIGNIFICANT ACROSS ALL DOSE GROUPS, WITH P-VALUE OF
|
XENON PHARMACEUTICALS PRESENTS ADDITIONAL POSITIVE DATA FROM PHASE 2B ‘X-TOLE' CLINICAL TRIAL AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES 2021)
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-03 06:55:00
| null |
BURNABY, BRITISH COLUMBIA, DEC. 03, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT WILL PROVIDE UPDATES ON ITS PROPRIETARY, NEUROLOGY PROGRAMS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES 2021).
|
XENON PHARMACEUTICALS PROVIDES UPDATES ON PROPRIETARY NEUROLOGY PIPELINE PROGRAMS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY (AES 2021)
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-08 14:15:00
| null |
BURNABY, BRITISH COLUMBIA, OCT. 08, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 10,000,000 COMMON SHARES, WHICH INCLUDES 1,525,423 SHARES SOLD UPON THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES, AND PRE-FUNDED WARRANTS TO PURCHASE 1,694,915 COMMON SHARES. THE COMMON SHARES WERE OFFERED AT A PUBLIC OFFERING PRICE OF $29.50 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS WERE OFFERED AT A PRICE OF $29.4999 PER PRE-FUNDED WARRANT, WITH EACH PRE-FUNDED WARRANT HAVING AN EXERCISE PRICE OF $0.0001. THE AGGREGATE GROSS PROCEEDS TO XENON FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY XENON, WERE APPROXIMATELY $345.0 MILLION.
|
XENON PHARMACEUTICALS ANNOUNCES CLOSING OF $345 MILLION PUBLIC OFFERING INCLUDING FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-05 21:54:00
| null |
BURNABY, BRITISH COLUMBIA, OCT. 05, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 8,474,577 COMMON SHARES AND, IN LIEU OF COMMON SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,694,915 COMMON SHARES PURSUANT TO ITS EXISTING SHELF REGISTRATION STATEMENT. THE COMMON SHARES ARE BEING OFFERED AT A PUBLIC OFFERING PRICE OF $29.50 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS ARE BEING OFFERED AT A PRICE OF $29.4999 PER PRE-FUNDED WARRANT. THE GROSS PROCEEDS TO XENON FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY XENON, ARE EXPECTED TO BE APPROXIMATELY $300.0 MILLION. IN ADDITION, XENON HAS GRANTED TO THE UNDERWRITERS OF THE OFFERING AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 1,525,423 COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT OCTOBER 8, 2021, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.
|
XENON PHARMACEUTICALS ANNOUNCES PRICING OF $300.0 MILLION PUBLIC OFFERING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-04 16:08:00
| null |
BURNABY, BRITISH COLUMBIA, OCT. 04, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ: XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $250 MILLION OF ITS COMMON SHARES PURSUANT TO ITS EXISTING SHELF REGISTRATION STATEMENT. IT IS EXPECTED THAT THE UNDERWRITERS OF THE OFFERING WILL BE GRANTED AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL $37.5 MILLION OF COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED.
|
XENON PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-23 08:30:00
| null |
BURNABY, BRITISH COLUMBIA, AUG. 23, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF CHRISTOPHER KENNEY, M.D. AS CHIEF MEDICAL OFFICER, EFFECTIVE IMMEDIATELY. DR. KENNEY WILL OVERSEE ALL CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS STRATEGIES, GUIDING THE DEVELOPMENT OF XENON'S PORTFOLIO OF NEUROLOGY-FOCUSED THERAPEUTIC PROGRAMS.
|
XENON PHARMACEUTICALS STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF DR. CHRISTOPHER KENNEY AS CHIEF MEDICAL OFFICER
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-10 17:53:00
| null |
BURNABY, BRITISH COLUMBIA, AUG. 10, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED ITS PARTICIPATION IN ONE-ON-ONE INVESTOR MEETINGS AS WELL AS A VIRTUAL PANEL DISCUSSION AT THE 12TH ANNUAL WEDBUSH PACGROW HEALTHCARE CONFERENCE.
|
XENON PHARMACEUTICALS TO PARTICIPATE IN THE 12TH ANNUAL WEDBUSH PACGROW HEALTHCARE CONFERENCE
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-07 08:30:00
| null |
WEBINAR TO BE BROADCAST LIVE ON MONDAY, JULY 12, 2021 BEGINNING AT 10 AM ET WEBINAR TO BE BROADCAST LIVE ON MONDAY, JULY 12, 2021 BEGINNING AT 10 AM ET
|
XENON PHARMACEUTICALS ANNOUNCES COMPLETION OF PATIENT RANDOMIZATION IN XEN1101 PHASE 2B “X-TOLE” CLINICAL TRIAL AND ANNOUNCES UPCOMING INVESTOR WEBINAR WITH LEADING EPILEPSY KEY OPINION LEADERS
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-03 17:45:00
| null |
BURNABY, BRITISH COLUMBIA, JUNE 03, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A NEUROLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY, PROVIDED A CORPORATE UPDATE FOLLOWING ITS 2021 ANNUAL MEETING OF SHAREHOLDERS (THE “ANNUAL MEETING”) HELD TODAY ON JUNE 3, 2021.
|
XENON PHARMACEUTICALS PROVIDES CORPORATE UPDATE FOLLOWING ITS ANNUAL MEETING OF SHAREHOLDERS
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-31 16:01:00
| null |
BURNABY, BRITISH COLUMBIA, MAY 31, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT MEMBERS OF ITS EXECUTIVE MANAGEMENT TEAM WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCE:
|
XENON PHARMACEUTICALS TO PRESENT AT THE JEFFERIES 2021 VIRTUAL HEALTHCARE CONFERENCE
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-08 16:03:00
| null |
BURNABY, BRITISH COLUMBIA, APRIL 08, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT MEMBERS OF ITS EXECUTIVE MANAGEMENT TEAM WILL PRESENT A CORPORATE OVERVIEW AND PARTICIPATE IN THE FOLLOWING VIRTUAL INVESTOR CONFERENCES:
|
XENON PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-29 16:05:00
| null |
BURNABY, BRITISH COLUMBIA, MARCH 29, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE FOLLOWING VIRTUAL INVESTOR CONFERENCE:
|
XENON PHARMACEUTICALS TO PARTICIPATE IN THE STIFEL 3RD ANNUAL CNS DAY
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-12 12:19:00
| null |
BURNABY, BRITISH COLUMBIA, MARCH 12, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,135,135 COMMON SHARES, WHICH INCLUDES 810,810 SHARES SOLD UPON THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES, AND PRE-FUNDED WARRANTS TO PURCHASE 1,081,081 COMMON SHARES. THE COMMON SHARES WERE OFFERED AT A PUBLIC OFFERING PRICE OF $18.50 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS WERE OFFERED AT A PRICE OF $18.4999 PER PRE-FUNDED WARRANT, WITH EACH PRE-FUNDED WARRANT HAVING AN EXERCISE PRICE OF $0.0001. THE AGGREGATE GROSS PROCEEDS TO XENON FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY XENON, WERE APPROXIMATELY $115.0 MILLION.
|
XENON PHARMACEUTICALS ANNOUNCES CLOSING OF $115 MILLION PUBLIC OFFERING AND FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 00:49:00
| null |
BURNABY, BRITISH COLUMBIA, MARCH 09, 2021 (GLOBE NEWSWIRE) -- XENON PHARMACEUTICALS INC. (NASDAQ:XENE), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 4,324,325 COMMON SHARES AND, IN LIEU OF COMMON SHARES TO A CERTAIN INVESTOR, PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,081,081 COMMON SHARES PURSUANT TO ITS EXISTING SHELF REGISTRATION STATEMENT. THE COMMON SHARES ARE BEING OFFERED AT A PUBLIC OFFERING PRICE OF $18.50 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS ARE BEING OFFERED AT A PRICE OF $18.4999 PER PRE-FUNDED WARRANT. THE GROSS PROCEEDS TO XENON FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY XENON, ARE EXPECTED TO BE APPROXIMATELY $100.0 MILLION. IN ADDITION, XENON HAS GRANTED TO THE UNDERWRITERS OF THE OFFERING AN OPTION FOR A PERIOD OF 30 DAYS TO PURCHASE UP TO AN ADDITIONAL 810,810 COMMON SHARES AT THE PUBLIC OFFERING PRICE, LESS THE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT MARCH 12, 2021, SUBJECT TO CUSTOMARY CLOSING CONDITIONS.
|
XENON PHARMACEUTICALS ANNOUNCES PRICING OF $100.0 MILLION PUBLIC OFFERING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-12-07 16:03:00
| null |
EARLY, PROMISING DATA FROM PHYSICIAN-LED PHASE 2 OPEN LABEL CLINICAL TRIAL SUPPORT XEN007 AS A POTENTIAL TREATMENT OF CHILDHOOD ABSENCE EPILEPSY (CAE) EARLY, PROMISING DATA FROM PHYSICIAN-LED PHASE 2 OPEN LABEL CLINICAL TRIAL SUPPORT XEN007 AS A POTENTIAL TREATMENT OF CHILDHOOD ABSENCE EPILEPSY (CAE)
|
XENON PHARMACEUTICALS PROVIDES UPDATES ON NEUROLOGY PIPELINE PROGRAMS AT AES2020, THE VIRTUAL ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-06 18:30:00
| null |
XENON PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.XENON PHARMACEUTICALS INC - XEN496 PHASE 3 PROTOCOL SUBMITTED TO FDA AND TRIAL INITIATION ANTICIPATED IN 2020.XENON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.00.XENON PHARMACEUTICALS INC - ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO 2022.
|
XENON PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-21 18:30:00
| null |
XENON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.ADDITIONAL FDA FEEDBACK SUPPORTS COMMENCEMENT OF XEN496 PHASE 3 CLINICAL TRIAL IN 2020.CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2020 WERE $229.7 MILLION.QTRLY LOSS PER SHARE $0.22.Q1 EARNINGS PER SHARE VIEW $-0.32 -- REFINITIV IBES DATA.
|
XENON PHARMACEUTICALS POSTS QUARTERLY LOSS PER SHARE $0.22
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-03-09 18:30:00
| null |
XENON PHARMACEUTICALS REPORTS 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.XENON PHARMACEUTICALS - ANTICIPATE TOP-LINE DATA FROM ONGOING XEN1101 PHASE 2B CLINICAL TRIAL IN ADULT FOCAL EPILEPSY LATER THIS YEAR.XENON PHARMACEUTICALS INC - EXPECT FDA FEEDBACK ON PHASE 3 PROTOCOL FOR XEN496 EARLY WITHIN Q2.
|
XENON PHARMACEUTICALS EXPECTS FDA FEEDBACK ON PHASE 3 PROTOCOL FOR XEN496 EARLY WITHIN Q2
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-06 11:30:00
| null |
XENON PHARMACEUTICALS PROVIDES UPDATES ON PROPRIETARY NEUROLOGY PIPELINE PROGRAMS AT 2019 AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING.XENON PHARMACEUTICALS - EPILEPSY PROGRAMS CONTINUE TO ADVANCE INCLUDING ONGOING XEN1101 PHASE 2B CLINICAL TRIAL IN ADULT FOCAL EPILEPSY.XENON PHARMACEUTICALS INC - PLANS FOR ANTICIPATED PEDIATRIC XEN496 PIVOTAL PHASE 3 CLINICAL TRIAL IN KCNQ2-DEE PATIENTS.XENON PHARMACEUTICALS - XEN1101 PHASE 2B CLINICAL TRIAL ONGOING WITH PATIENT ENROLLMENT IN U.S., CANADA, EUROPE & TOP-LINE DATA EXPECTED IN H2 2020.XENON PHARMACEUTICALS INC - EXPECTS TO FILE AN IND APPLICATION IN Q1 2020 TO DISCUSS WITH FDA DESIGN OF A PHASE 3 CLINICAL TRIAL IN KCNQ2-DEE.
|
XENON PHARMACEUTICALS PROVIDES UPDATES ON PROPRIETARY NEUROLOGY PIPELINE PROGRAMS AT 2019 AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-05 22:30:00
| null |
XENON PHARMACEUTICALS INC. ANNOUNCED THAT IT WILL PROVIDE UPDATES ON ITS PROPRIETARY, NEUROLOGY PROGRAMS AT THE AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING HELD IN BALTIMORE, MD. XENON IS PRESENTING UPDATES ON BOTH OF ITS PROPRIETARY, CLINICAL-STAGE PROGRAMS, XEN1101 AND XEN496 – AS WELL AS PRESENTING PROMISING PRE-CLINICAL DATA – IN A NUMBER OF POSTER SESSIONS AT AES: XEN496 (ACTIVE INGREDIENT EZOGABINE) IS A KV7 POTASSIUM CHANNEL MODULATOR BEING DEVELOPED BY XENON. A POSTER ENTITLED DEVELOPMENT OF A PEDIATRIC IMMEDIATE-RELEASE FORMULATION OF THE POTASSIUM CHANNEL OPENER XEN496 (EZOGABINE) WILL BE PRESENTED IN A SCIENTIFIC POSTER SESSION, AS WELL AS THE BIOMARIN EXHIBIT, ON DECEMBER 8, 2019. AFTER EXAMINING MULTIPLE FORMULATIONS WITH DIFFERENT PROPERTIES, XENON HAS DEVELOPED XEN496 AS A PEDIATRIC-SPECIFIC, GRANULE FORMULATION TO BE PACKAGED AS SINGLE-DOSE SPRINKLE CAPSULES THAT HAS EXCELLENT PROPERTIES SUPPORTED BY BOTH IN VITRO AND IN VIVO DATA. A PLANNED PHARMACOKINETIC (PK) STUDY WILL TEST XEN496 IN HEALTHY ADULT VOLUNTEERS, WITH DATA EXPECTED IN THE FIRST QUARTER OF 2020. XENON WILL ALSO PRESENT A POSTER IN THE BIOMARIN EXHIBIT ENTITLED, AN ONLINE SURVEY OF CAREGIVERS OF PATIENTS WITH KCNQ2 DEVELOPMENTAL & EPILEPTIC ENCEPHALOPATHY (KCNQ2-DEE). XENON RECENTLY PERFORMED A CAREGIVER SURVEY TO OBTAIN ADDITIONAL PHENOTYPIC INFORMATION REGARDING THE SEIZURE HISTORY OF THE DISEASE AS WELL AS ANTI-SEIZURE MEDICATION (ASM) USE, WITH A FOCUS ON EZOGABINE. IMPORTANTLY, ALL SEVEN RESPONDENTS WHO HAD ACCESS TO EZOGABINE RESPONDED THAT THEY SAW IMPROVEMENTS IN THEIR CHILD’S SEIZURES, BEHAVIOR OR DEVELOPMENT WHILE THEY WERE TAKING EZOGABINE. IN ADDITION, EZOGABINE WAS REPORTED TO BE WELL-TOLERATED. INFORMATION FROM THIS SURVEY, AS WELL AS INPUT FROM KEY OPINION LEADERS, WILL HELP INFORM THE PROPOSED PHASE 3 CLINICAL TRIAL DESIGN AND PROTOCOL. XENON EXPECTS TO FILE AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION IN THE FIRST QUARTER OF 2020 TO DISCUSS WITH THE FDA THE DESIGN OF A PHASE 3 CLINICAL TRIAL IN KCNQ2-DEE. THE FDA HAS INDICATED THAT IT IS ACCEPTABLE TO STUDY XEN496 IN INFANTS AND CHILDREN UP TO FOUR YEARS OLD, AND THAT A SINGLE, SMALL PIVOTAL TRIAL MAY BE CONSIDERED ADEQUATE IN ORDER TO DEMONSTRATE XEN496’S EFFICACY IN KCNQ2-DEE, PROVIDED THE STUDY SHOWS EVIDENCE OF A CLINICALLY MEANINGFUL BENEFIT IN PATIENTS WITH THE INTENDED INDICATION. XEN1101 IS A DIFFERENTIATED KV7 POTASSIUM CHANNEL MODULATOR BEING DEVELOPED FOR THE TREATMENT OF EPILEPSY AND POTENTIALLY OTHER NEUROLOGICAL DISORDERS. A POSTER ENTITLED USE OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) DATA IN THE DESIGN OF A DOSE RANGE FINDING EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS STUDY OF XEN1101 IN PATIENTS WITH FOCAL EPILEPSY WILL BE PRESENTED ON DECEMBER 9, 2019. THIS POSTER OUTLINES THE XEN1101 PHASE 2 STUDY DESIGN AND CONCLUDES THAT INCORPORATING TMS EVIDENCE OF CNS ACTIVITY IN HEALTHY VOLUNTEERS MAY BE A USEFUL ADJUNCT IN REFINING DOSE SELECTION FOR PHASE 2 EPILEPSY STUDIES. A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL TRIAL (CALLED THE X-TOLE STUDY), WHICH IS CURRENTLY UNDERWAY TO EVALUATE THE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF XEN1101 ADMINISTERED AS ADJUNCTIVE TREATMENT IN APPROXIMATELY 300 ADULT PATIENTS WITH FOCAL EPILEPSY. THE PRIMARY ENDPOINT IS THE MEDIAN PERCENT CHANGE IN MONTHLY FOCAL SEIZURE FREQUENCY FROM BASELINE COMPARED TO TREATMENT PERIOD OF ACTIVE VERSUS PLACEBO. PATIENT ENROLLMENT FOR THIS XEN1101 PHASE 2B CLINICAL TRIAL IS ONGOING IN THE UNITED STATES, CANADA AND EUROPE. LONG TERM SIX AND NINE-MONTH TOXICOLOGY STUDIES HAVE NOW BEEN COMPLETED, PROVIDING SUPPORT TO THE PLANNED 12-MONTH OPEN LABEL EXTENSION FOR PATIENTS ENROLLED IN THE PHASE 2B CLINICAL TRIAL. DEPENDING UPON THE RATE OF ENROLLMENT, TOP-LINE RESULTS ARE ANTICIPATED IN THE SECOND HALF OF 2020. XENON ALSO CONTINUES TO CONDUCT PRE-CLINICAL WORK ON OTHER PROMISING MOLECULES TO ADDRESS NEUROLOGICAL DISORDERS. A POSTER ENTITLED, SMALL MOLECULE POTENTIATORS OF NAV1.1 INCREASE ACTION POTENTIAL FIRING IN FAST SPIKING CORTICAL INHIBITORY INTERNEURONS FROM A MOUSE MODEL OF DRAVET SYNDROME – WHICH WILL BE PRESENTED ON DECEMBER 9, 2019 – OUTLINES PROMISING WORK ON HIGHLY SELECTIVE SMALL MOLECULE POTENTIATORS OF NAV1.1 THAT COULD ADDRESS THE UNDERLYING CAUSE OF DRAVET SYNDROME USING A PRECISION MEDICINE APPROACH. SELECTIVELY POTENTIATING NAV1.1, THE DOMINANT SODIUM CHANNEL ISOFORM EXPRESSED IN INHIBITORY INTERNEURONS, RESTORES THE CAPABILITY OF SCN1A+/- INTERNEURONS TO FIRE ACTION POTENTIALS AT HIGH FREQUENCY. IN BRAIN SLICES FROM SCN1A+/- MICE, THE TESTED COMPOUND INCREASED THE FIRING RATE OF INHIBITORY NEURONS. A SMALL MOLECULE PHARMACEUTICAL WITH THIS PROFILE COULD ENABLE REVERSAL OF THE FUNDAMENTAL DEFECT IN DRAVET SYNDROME AND MAY HAVE UTILITY IN OTHER NEUROLOGIC INDICATIONS WHERE INTERNEURON EXCITABILITY IS IMPAIRED. XENON INTENDS TO BUILD UPON THIS PROMISING WORK AND CONTINUE TO ADVANCE POTENTIAL NAV1.1 POTENTIATORS IN PRE-CLINICAL DEVELOPMENT.
|
XENON PHARMACEUTICALS INC. PROVIDES UPDATES ON PROPRIETARY NEUROLOGY PIPELINE PROGRAMS AT THE 2019 AMERICAN EPILEPSY SOCIETY (AES) ANNUAL MEETING
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-02 22:30:00
| null |
XENON PHARMACEUTICALS INC. PRESENTS AT PIPER JAFFRAY 31ST ANNUAL HEALTHCARE CONFERENCE, DEC-04-2019 03:00 PM. VENUE: THE LOTTE NEW YORK PALACE, 455 MADISON AVENUE, NEW YORK, NEW YORK, UNITED STATES. SPEAKERS: SIMON N. PIMSTONE, CEO & DIRECTOR.
|
XENON PHARMACEUTICALS INC. PRESENTS AT PIPER JAFFRAY 31ST ANNUAL HEALTHCARE CONFERENCE, DEC-04-2019 03:00 PM
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-12-02 10:30:00
| null |
NEUROCRINE BIOSCIENCES AND XENON PHARMACEUTICALS ANNOUNCE AGREEMENT TO DEVELOP TREATMENTS FOR EPILEPSY.NEUROCRINE BIOSCIENCES INC - CO GAINS RIGHTS TO XEN901, BEING DEVELOPED FOR TREATMENT OF EPILEPSY.NEUROCRINE BIOSCIENCES INC - XENON WILL RECEIVE UP TO $25 MILLION UPON FDA ACCEPTANCE OF AN IND FOR XEN901.NEUROCRINE BIOSCIENCES - XENON TO RECEIVE $50 MILLION, INCLUDING $30 MILLION IN CASH, $20 MILLION EQUITY INVESTMENT BY CO AT XENON PER SHARE PRICE OF $14.196.NEUROCRINE BIOSCIENCES - UNDER TERMS OF AGREEMENT WITH XENON, CO WILL BE RESPONSIBLE FOR DEVELOPMENT COSTS ASSOCIATED WITH PROGRAMS.
|
NEUROCRINE BIOSCIENCES AND XENON PHARMACEUTICALS AGREES TO DEVELOP TREATMENTS FOR EPILEPSY
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-17 22:30:00
| null |
XENON PHARMACEUTICALS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 03:35 PM. VENUE: LOTTE NEW YORK PALACE HOTEL, NEW YORK, NEW YORK, UNITED STATES.
|
XENON PHARMACEUTICALS INC. PRESENTS AT STIFEL 2019 HEALTHCARE CONFERENCE, NOV-19-2019 03:35 PM
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-14 22:30:00
| null |
XENON PHARMACEUTICALS INC. PRESENTS AT GUGGENHEIM HEALTHCARE TALKS | IDEA FORUM | NEURO/IMMUNOLOGY DAY, NOV-18-2019 . VENUE: ST. REGIS NEW YORK - THE ROOF, NEW YORK, NEW YORK, UNITED STATES. SPEAKERS: SIMON N. PIMSTONE, CEO & DIRECTOR.
|
XENON PHARMACEUTICALS INC. PRESENTS AT GUGGENHEIM HEALTHCARE TALKS | IDEA FORUM | NEURO/IMMUNOLOGY DAY, NOV-18-2019
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-05 20:30:00
| null |
XENON PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 REVENUE $3.5 MILLION.Q3 REVENUE ESTIMATE $0 -- REFINITIV IBES DATA.QUARTERLY LOSS PER SHARE $0.33.
|
XENON PHARMACEUTICALS INC REPORTS Q3 REVENUE OF $3.5 MLN
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-04 22:30:00
| null |
XENON PHARMACEUTICALS INC. ANNOUNCED EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019. FOR THE THIRD QUARTER, THE COMPANY ANNOUNCED SALES WAS USD 3.500 MILLION COMPARED TO USD 0 A YEAR AGO. OPERATING LOSS WAS USD 8.951 MILLION COMPARED TO USD 14.186 MILLION A YEAR AGO. NET LOSS WAS USD 8.871 MILLION COMPARED TO USD 14.383 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 0.33 COMPARED TO USD 0.63 A YEAR AGO. FOR THE NINE MONTHS, SALES WAS USD 3.500 MILLION COMPARED TO USD 0 A YEAR AGO. OPERATING LOSS WAS USD 31.221 MILLION COMPARED TO USD 29.586 MILLION A YEAR AGO. NET LOSS WAS USD 30.219 MILLION COMPARED TO USD 25.939 MILLION A YEAR AGO. BASIC LOSS PER SHARE WAS USD 1.13 COMPARED TO USD 1.34 A YEAR AGO.
|
XENON PHARMACEUTICALS INC. REPORTS EARNINGS RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2019
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-28 22:30:00
| null |
XENON PHARMACEUTICALS INC., Q3 2019 EARNINGS CALL, NOV 05, 2019
|
XENON PHARMACEUTICALS INC., Q3 2019 EARNINGS CALL, NOV 05, 2019
|
XENE
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-25 07:00:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--REAL-WORLD EVIDENCE STUDY DEMONSTRATES INTERSECT ENT'S PROPEL® SINUS IMPLANT REDUCES HEALTHCARE RESOURCE UTILIZATION
|
REAL-WORLD EVIDENCE STUDY DEMONSTRATES INTERSECT ENT'S PROPEL® SINUS IMPLANT REDUCES HEALTHCARE RESOURCE UTILIZATION
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-13 15:23:00
| null |
NEW YORK, SEPT. 13, 2021 /PRNEWSWIRE/ -- JUAN MONTEVERDE , FOUNDER AND MANAGING PARTNER AT MONTEVERDE & ASSOCIATES PC, A NATIONAL SECURITIES FIRM RATED TOP 50 IN THE 2018-2020 ISS SECURITIES CLASS ACTION SERVICES REPORT AND HEADQUARTERED AT THE EMPIRE STATE BUILDING IN NEW YORK CITY, IS INVESTIGATING INTERSECT ENT, INC. ("XENT" OR THE "COMPANY") (XENT) RELATING TO ITS PROPOSED ACQUISITION BY MEDTRONIC PLC.
|
SHAREHOLDER ALERT: MONTEVERDE & ASSOCIATES PC ANNOUNCES AN INVESTIGATION OF INTERSECT ENT, INC. - XENT
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-09 14:47:00
| null |
NEW YORK, AUG. 9, 2021 /PRNEWSWIRE/ -- ROWLEY LAW PLLC IS INVESTIGATING POTENTIAL SECURITIES LAW VIOLATIONS BY INTERSECT ENT, INC. (NASDAQ: XENT) AND ITS BOARD OF DIRECTORS CONCERNING THE PROPOSED ACQUISITION OF THE COMPANY BY MEDTRONIC PLC (NYSE: MDT). STOCKHOLDERS WILL RECEIVE $28.25 FOR EACH SHARE OF INTERSECT ENT STOCK THAT THEY HOLD.
|
ALERT: ROWLEY LAW PLLC IS INVESTIGATING PROPOSED ACQUISITION OF INTERSECT ENT, INC.
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-06 16:31:00
| null |
NEW YORK, AUG. 6, 2021 /PRNEWSWIRE/ -- WEISSLAW LLP IS INVESTIGATING POSSIBLE BREACHES OF FIDUCIARY DUTY AND OTHER VIOLATIONS OF LAW BY THE BOARD OF DIRECTORS OF INTERSECT ENT, INC. ("INTERSECT" OR THE "COMPANY") (NASDAQ: XENT) IN CONNECTION WITH THE PROPOSED ACQUISITION OF THE COMPANY BY MEDTRONIC PLC ("MEDTRONIC") (NYSE:MDT). UNDER THE TERMS OF THE MERGER AGREEMENT, THE COMPANY'S SHAREHOLDERS WILL RECEIVE $28.25 PER SHARE IN CASH FOR EACH SHARE OF INTERSECT COMMON STOCK THAT THEY HOLD.
|
SHAREHOLDER ALERT: WEISSLAW LLP INVESTIGATES INTERSECT ENT, INC.
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-06 12:45:00
| null |
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLP, A GLOBAL INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER THE SALE OF INTERSECT ENT, INC. (NASDAQ: XENT) TO MEDTRONIC PLC FOR $28.25 PER SHARE IS FAIR TO INTERSECT ENT SHAREHOLDERS. HALPER SADEH ENCOURAGES INTERSECT ENT SHAREHOLDERS TO CLICK HERE TO LEARN MORE ABOUT THEIR LEGAL RIGHTS AND OPTIONS OR CONTACT DANIEL SADEH OR ZACHARY HALPER AT (212) 763-0060 OR SADEH@HALPERSADEH.COM OR ZHALPER@HALPERSADEH.COM. THE INVESTIGATION CONCERNS WHETHER INTERS
|
INTERSECT ENT MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF INTERSECT ENT, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – XENT
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-06 12:12:00
| null |
MILWAUKEE, AUG. 6, 2021 /PRNEWSWIRE/ -- ADEMI LLP IS INVESTIGATING INTERSECT ENT (NASDAQ: XENT) FOR POSSIBLE BREACHES OF FIDUCIARY DUTY AND OTHER VIOLATIONS OF LAW IN ITS TRANSACTION WITH MEDTRONIC. CLICK HERE TO LEARN HOW TO JOIN THE ACTION: HTTPS://WWW.ADEMILAW.COM/CASE/INTERSECT-ENT-INC OR CALL GURI ADEMI TOLL-FREE AT 866-264-3995.
|
SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER INTERSECT ENT, INC. HAS OBTAINED A FAIR PRICE IN ITS TRANSACTION WITH MEDTRONIC
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-06 07:15:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT, INC. (NASDAQ: XENT), A GLOBAL EAR, NOSE AND THROAT (“ENT”) MEDICAL TECHNOLOGY LEADER DEDICATED TO TRANSFORMING PATIENT CARE, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021. SECOND QUARTER 2021 OVERVIEW ENTERED INTO A DEFINITIVE AGREEMENT WITH MEDTRONIC, IN WHICH MEDTRONIC WILL ACQUIRE ALL OUTSTANDING SHARES OF INTERSECT ENT. REVENUE OF $27.3 MILLION IN THE SECOND QUARTER OF 2021, UP 180%, COMPARED TO $9.8 MILLION I
|
INTERSECT ENT REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-26 07:00:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT®, INC. (NASDAQ: XENT), A GLOBAL EAR, NOSE AND THROAT (“ENT”) MEDICAL TECHNOLOGY LEADER DEDICATED TO TRANSFORMING PATIENT CARE, TODAY ANNOUNCED THE U.S. NATIONWIDE COMMERCIAL AVAILABILITY OF THE VENSURE™ BALLOON SINUS DILATION SYSTEM AND CUBE™4D NAVIGATION SYSTEM WITH VIRTUEYE™ PHOTO REGISTRATION. THE VENSURE BALLOON AND CUBE 4D NAVIGATION SYSTEMS ARE USED IN PROCEDURES THAT ARE DESIGNED TO IMPROVE DEBILITATING CHRONIC RHINOSINUSITIS (CRS) SYMPT
|
U.S NATIONWIDE COMMERCIAL AVAILABILITY OF THE VENSURE™ BALLOON SINUS DILATION SYSTEM AND CUBE™ NAVIGATION SYSTEM HIGHLIGHT INTERSECT ENT'S CONTINUED COMMITMENT TO PROVIDING INNOVATIVE, SOLUTIONS FOR PATIENTS WITH CHRONIC RHINOSINUSITIS
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-07-22 16:05:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT ANNOUNCES PRELIMINARY REVENUE FOR SECOND QUARTER OF 2021 AND CLOSING OF $60 MILLION TERM LOAN
|
INTERSECT ENT ANNOUNCES PRELIMINARY REVENUE FOR SECOND QUARTER OF 2021 AND CLOSING OF $60 MILLION TERM LOAN
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-05 16:05:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
|
INTERSECT ENT ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-10 08:30:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT TO PARTICIPATE AT THE OPPENHEIMER 31ST ANNUAL HEALTHCARE CONFERENCE
|
INTERSECT ENT TO PARTICIPATE AT THE OPPENHEIMER 31ST ANNUAL HEALTHCARE CONFERENCE
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-09 07:00:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT REPORTS FOURTH QUARTER 2020 FINANCIAL RESULTS
|
INTERSECT ENT REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-03-08 07:00:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT®, INC. (NASDAQ: XENT), A GLOBAL EAR, NOSE AND THROAT (“ENT”) MEDICAL TECHNOLOGY LEADER DEDICATED TO TRANSFORMING PATIENT CARE, TODAY ANNOUNCED THAT THE CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) PUBLISHED AN AVERAGE SELLING PRICE (ASP) FOR THE COMPANY'S SINUVA SINUS IMPLANT, PROVIDING PREDICTABILITY, TRANSPARENCY, AND CONFIDENCE OF REIMBURSEMENT FOR PROVIDERS AND PAYERS GOING FORWARD. IN JANUARY 2021, CMS CREATED SEPARATE AND DISTINCT COD
|
CMS CONSOLIDATES SINUVA SINUS IMPLANT COVERAGE UNDER A DISTINCT CODE, J7402, AND PUBLISHES AN ASP CLARIFYING PAYMENT AND EASING PAYER COVERAGE ADJUDICATION
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-02-11 07:00:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT®, INC. (NASDAQ: XENT), A GLOBAL EAR, NOSE AND THROAT (“ENT”) MEDICAL TECHNOLOGY LEADER DEDICATED TO TRANSFORMING PATIENT CARE, TODAY ANNOUNCED THE U.S. AVAILABILITY OF THE NEW STRAIGHT DELIVERY SYSTEM (“SDS”) PACKAGED WITH THE COMPANY'S PROPEL® MINI (MOMETASONE FUROATE) SINUS IMPLANT. THE COMBINED PACKAGING OF THE SDS WITH PROPEL MINI RECEIVED PREMARKET APPROVAL (“PMA”) BY THE U.S. FOOD AND DRUG ADMINISTRATION (“FDA”) WHICH FOLLOWS PMA FOR THE
|
INTERSECT ENT ANNOUNCES LAUNCH OF THE NEW STRAIGHT DELIVERY SYSTEM PACKAGED WITH THE PROPEL® MINI SINUS IMPLANT
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-01-19 07:00:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT ANNOUNCES CMS APPROVAL OF CODING APPLICATION FOR PROPEL® SINUS IMPLANT
|
INTERSECT ENT ANNOUNCES CMS APPROVAL OF CODING APPLICATION FOR PROPEL® SINUS IMPLANT
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-11-17 16:45:00
| null |
MENLO PARK, CALIF.--(BUSINESS WIRE)--INTERSECT ENT ANNOUNCES NEW APPOINTMENTS TO EXECUTIVE LEADERSHIP TEAM
|
INTERSECT ENT ANNOUNCES NEW APPOINTMENTS TO EXECUTIVE LEADERSHIP TEAM
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-08-04 09:30:00
| null |
INTERSECT ENT REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 ADJUSTED LOSS PER SHARE $0.65.Q2 LOSS PER SHARE $0.71.Q2 REVENUE $9.8 MILLION VERSUS $26.7 MILLION.Q2 REVENUE ESTIMATE $5.4 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.56 -- REFINITIV IBES DATA.SINUVA PATIENT REFERRALS ALSO EXPERIENCED A PROGRESSIVE RISE THROUGHOUT QUARTER.INTERSECT ENT - ANTICIPATE CONTINUED INCREASES IN ELECTIVE SINUS PROCEDURES THAT WILL DRIVE SEQUENTIAL REVENUE GROWTH DURING SECOND HALF OF 2020.EXPECTS A SEQUENTIAL INCREASE IN REVENUES DURING SECOND HALF OF 2020 FROM Q2 2020 LEVELS.BELIEVES IT WILL ALSO RETURN TO GROSS MARGIN LEVELS IN MID-70% RANGE BY YEAR END 2020.CONTINUES TO BELIEVE IT HAS ADEQUATE CAPITAL TO OPERATE EFFECTIVELY THROUGH 2022.
|
INTERSECT ENT Q2 LOSS PER SHARE $0.71
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-06-15 11:30:00
| null |
INTERSECT ENT - ON JUNE 11, UPDATED REVENUE GUIDANCE FOR SECOND FISCAL QUARTER ENDING JUNE 30, 2020.INTERSECT ENT - DISCLOSED IT HAS SEEN A MEANINGFUL RECOVERY IN REVENUE IN MAY & BEGINNING OF JUNE 2020.INTERSECT ENT - UPDATED Q2 REVENUE OUTLOOK TO A REVISED ESTIMATE OF ABOUT 70-75% DECLINE FROM PRIOR YEAR, & PERHAPS BETTER.
|
INTERSECT ENT UPDATES REVENUE GUIDANCE FOR Q2
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-05-11 10:30:00
| null |
INTERSECT ENT REPORTS FIRST QUARTER 2020 RESULTS.Q1 REVENUE $19.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $23.7 MILLION.REDUCED TOTAL WORKFORCE BY APPROXIMATELY 25% AND FURLOUGHED ADDITIONAL 5%.QTRLY LOSS PER SHARE $0.54.
|
INTERSECT ENT REPORTS FIRST QUARTER 2020 RESULTS
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-04-13 18:30:00
| null |
INTERSECT ENT ANNOUNCES PRELIMINARY REVENUE FOR FIRST QUARTER 2020 AND PROVIDES BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC.SEES Q1 2020 REVENUE $19.5 MILLION TO $19.8 MILLION.PRELIMINARY UNAUDITED Q1 2020 REVENUE EXPECTED TO BE $19.5 TO $19.8 MILLION.COMPANY WITHDRAWS FULL YEAR 2020 GUIDANCE.Q1 NET SALES ARE EXPECTED TO BE IN RANGE OF $19.5 TO $19.8 MILLION, COMPARED TO $26.7 MILLION IN Q1 OF 2019.CASH AND MARKETABLE SECURITIES ARE EXPECTED TO BE IN RANGE OF $87.0 TO $88.0 MILLION AS OF MARCH 31, 2020.HAS TAKEN PRE-EMPTIVE ACTIONS TO CURTAIL SPENDING AS REVENUES ARE MATERIALLY IMPACTED.COST REDUCTION ACTIONS INCLUDE FURLOUGHING AND REDUCING ITS WORKFORCE, FREEZING NEW HIRING, SUSPENDING NEAR-TERM PRODUCTION.INTERSECT ENT - COST REDUCTION ACTIONS INCLUDE REDUCING DISCRETIONARY OPERATING EXPENSES & CAPITAL EXPENDITURES, DELAYING CLINICAL RESEARCH PROJECTS.IS WITHDRAWING ITS PREVIOUSLY ANNOUNCED ANNUAL GUIDANCE FOR 2020, WHICH WAS ISSUED ON FEBRUARY 24, 2020.CANNOT PREDICT EXTENT OR DURATION OF IMPACT OF COVID-19 PANDEMIC ON ITS FINANCIAL AND OPERATING RESULTS.BUSINESS HAS AND WILL BE IMPACTED BY HOSPITALS SUSPENDING ELECTIVE SURGICAL PROCEDURES AND REDUCED ENT OFFICE VISITS.Q1 REVENUE VIEW $26.6 MILLION -- REFINITIV IBES DATA.
|
INTERSECT ENT INC ANNOUNCES PRELIM REVENUE FOR Q1 2020
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2020-01-13 10:30:00
| null |
INTERSECT ENT REPORTS PRELIMINARY FULL YEAR 2019 REVENUE.SEES FY 2020 REVENUE $115 MILLION TO $119 MILLION.INTERSECT ENT - PRELIMINARY UNAUDITED REVENUE FOR FULL YEAR 2019 IS EXPECTED TO BE APPROXIMATELY $109 MILLION, IN LINE WITH GUIDANCE GIVEN IN MIDYEAR 2019.EXPECTED 2019 REVENUE INCLUDES PRELIMINARY SINUVA REVENUE OF APPROXIMATELY $4.5 MILLION FOR FULL YEAR 2019.FY2019 REVENUE VIEW $108.7 MILLION -- REFINITIV IBES DATA.FY2020 REVENUE VIEW $119.7 MILLION -- REFINITIV IBES DATA.
|
INTERSECT ENT SEES FY 2020 REVENUE $115 MLN TO $119 MLN
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-27 10:30:00
| null |
INTERSECT ENT ANNOUNCES APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER.RICHARD MEIER TO SERVE AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.SAYS RICHARD A. MEIER APPOINTED CFO.JERYL HILLEMAN HAS AGREED TO REMAIN IN AN ADVISORY CAPACITY INTO 2020 TO ASSIST WITH MEIER'S TRANSITION.MEIER PREVIOUSLY SERVED AS CFO AND SENIOR EXECUTIVE OF OWENS & MINOR, INC..
|
INTERSECT ENT SAYS RICHARD MEIER TO SERVE AS CFO
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-26 22:30:00
| null |
INTERSECT ENT®, INC. ANNOUNCED THE APPOINTMENT OF RICHARD A. (RANDY) MEIER AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE NOVEMBER 26, 2019. MR. MEIER PREVIOUSLY SERVED AS THE CHIEF FINANCIAL OFFICER AND SENIOR EXECUTIVE OF OWENS & MINOR, INC., INCLUDING AS PRESIDENT-INTERNATIONAL AND EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER OF OWENS & MINOR FROM 2013 TO 2018, AND AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER FROM 2013 TO 2015. PRIOR TO JOINING OWENS AND MINOR, MEIER SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER AT TELEFLEX, INC., FROM 2010 TO 2012. HE SERVED AS PRESIDENT AND CHIEF OPERATING OFFICER OF ADVANCED MEDICAL OPTICS, INC., FROM 2007 TO 2009, WHEN THE COMPANY WAS ACQUIRED AS A WHOLLY OWNED SUBSIDIARY OF ABBOTT LABORATORIES. MEIER JOINED ADVANCED MEDICAL OPTICS, A GLOBAL OPHTHALMIC MEDICAL DEVICE COMPANY, AS CORPORATE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER IN 2002 AND CONTINUOUSLY SERVED AS CHIEF FINANCIAL OFFICER WHILE SIMULTANEOUSLY PERFORMING IN A VARIETY OF FINANCE AND OPERATIONS ROLES BETWEEN 2002 AND 2007. MEIER ALSO WORKED FOR ICN PHARMACEUTICALS INC., NOW BAUSCH HEALTH, FROM 1998 TO 2002, WHERE HE SERVED AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, AND AS TREASURER. MEIER SERVES ON THE BOARD OF BIOMARIN PHARMACEUTICALS, INC., WHERE HE IS LEAD INDEPENDENT DIRECTOR. AS PREVIOUSLY ANNOUNCED, JERYL (JERI) HILLEMAN, INTERSECT ENT’S PRIOR CHIEF FINANCIAL OFFICER, STEPPED DOWN FROM THE POSITION AS PART OF A PLANNED TRANSITION ALLOWING HER TO FOCUS ON BOARD RESPONSIBILITIES OUTSIDE OF INTERSECT ENT. MS. HILLEMAN HAS AGREED TO REMAIN IN AN ADVISORY CAPACITY INTO 2020 TO ASSIST WITH MR. MEIER’S TRANSITION.
|
INTERSECT ENT®, INC. APPOINTS RICHARD A. MEIER AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-11-18 22:30:00
| null |
INTERSECT ENT, INC. PRESENTS AT PIPER JAFFRAY 31ST ANNUAL HEALTHCARE CONFERENCE, DEC-04-2019 04:30 PM. VENUE: THE LOTTE NEW YORK PALACE, 455 MADISON AVENUE, NEW YORK, NEW YORK, UNITED STATES.
|
INTERSECT ENT, INC. PRESENTS AT PIPER JAFFRAY 31ST ANNUAL HEALTHCARE CONFERENCE, DEC-04-2019 04:30 PM
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-31 22:30:00
| null |
INTERSECT ENT, INC. PROVIDED EARNINGS GUIDANCE FOR THE FULL YEAR OF FISCAL 2019. THE COMPANY IS MAINTAINING ITS OUTLOOK FOR REVENUE FOR THE FULL YEAR 2019 TO BE APPROXIMATELY FLAT COMPARED WITH 2018 REVENUE OF $108.5 MILLION.
|
INTERSECT ENT, INC. PROVIDES EARNINGS GUIDANCE FOR THE FULL YEAR OF FISCAL 2019
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-16 22:30:00
| null |
INTERSECT ENT, INC., Q3 2019 EARNINGS CALL, NOV 01, 2019
|
INTERSECT ENT, INC., Q3 2019 EARNINGS CALL, NOV 01, 2019
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-07 10:30:00
| null |
INTERSECT ENT ANNOUNCES RESULTS FROM THE ASCEND STUDY OF COMPANY’S INVESTIGATIONAL DRUG-COATED BALLOON FOR SINUS DILATION.INTERSECT ENT INC - TRIAL DID NOT MEET ITS PRIMARY ENDPOINT.INTERSECT ENT INC - ASCEND DRUG-COATED BALLOON SHOWED STATISTICALLY SIGNIFICANT DIFFERENCES IN SEVERAL IMPORTANT SECONDARY ENDPOINTS.INTERSECT ENT INC - THERE WERE NO ADVERSE EVENTS RELATED TO DRUG COMPONENT OF ASCEND BALLOON.
|
INTERSECT SAYS RESULTS FROM THE ASCEND STUDY OF CO’S INVESTIGATIONAL DRUG-COATED BALLOON FOR SINUS DILATION
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2019-10-06 22:30:00
| null |
INTERSECT ENT®, INC. ANNOUNCED RESULTS FROM A STUDY OF THE COMPANY’S ASCEND INVESTIGATIONAL DRUG-COATED SINUS BALLOON. THE ASCEND STUDY IS THE FIRST PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER TRIAL DESIGNED TO ASSESS THE SAFETY AND EFFICACY OF INTERSECT ENT’S DRUG-COATED SINUS BALLOON USED TO DILATE THE FRONTAL SINUS OSTIUM. THE INVESTIGATIONAL ASCEND PRODUCT WAS RANDOMIZED AGAINST AN UNCOATED BALLOON CONTROL TO EVALUATE WHETHER IT WOULD REDUCE POST-BALLOON DILATION EDEMA THROUGH LOCALIZED STEROID DELIVERY DIRECTLY TO THE DILATED TISSUE. THE PRIMARY ENDPOINT WAS AN INTRA-PATIENT COMPARISON OF FRONTAL SINUS PATENCY GRADE AT DAY 30, AS JUDGED BY AN INDEPENDENT REVIEWER. SECONDARY ENDPOINTS WERE INCLUDED TO ASSESS POST-DILATION INFLAMMATION, POLYPOID EDEMA, SCARRING AND THE NEED FOR INTERVENTIONS SUCH AS ORAL STEROIDS. AS THE FIRST TRIAL OF ITS KIND FOR THIS PRODUCT PLATFORM, THE COMPANY RECOGNIZED THAT THE OUTCOMES OF THE ASCEND TRIAL COULD REQUIRE FURTHER CLINICAL STUDY TO SUPPORT PMA APPROVAL WITH THE U.S. FOOD AND DRUG ADMINISTRATION. THE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT OF FRONTAL SINUS PATENCY GRADE AT DAY 30, AS JUDGED BY AN INDEPENDENT REVIEWER. HOWEVER, THE ASCEND DRUG-COATED BALLOON SHOWED STATISTICALLY SIGNIFICANT DIFFERENCES IN SEVERAL IMPORTANT SECONDARY ENDPOINTS DIRECTLY ATTRIBUTABLE TO THE DRUG, MOMETASONE FUROATE. THESE ENDPOINTS INCLUDED STATISTICALLY SIGNIFICANT REDUCTION IN INFLAMMATION AND POLYPOID EDEMA AT ALL TIMEPOINTS THROUGH DAY 30, AS ASSESSED BY BOTH THE CLINICAL INVESTIGATORS AND THE INDEPENDENT REVIEWER. THERE WAS ALSO A STATISTICALLY SIGNIFICANT REDUCTION IN THE NEED FOR ORAL STEROID INTERVENTIONS AT DAY 30, AS DETERMINED BY THE INDEPENDENT REVIEWER. THERE WERE NO ADVERSE EVENTS RELATED TO THE DRUG COMPONENT OF THE ASCEND BALLOON, AND NO DEVICE-RELATED SERIOUS ADVERSE EVENTS OBSERVED IN THE STUDY.
|
INTERSECT ENT ANNOUNCES RESULTS FROM THE ASCEND STUDY OF COMPANY’S INVESTIGATIONAL DRUG-COATED BALLOON FOR SINUS DILATION
|
XENT
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-18 08:05:00
| null |
BOCA RATON, FLA., JULY 18, 2023 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT” OR “THE COMPANY”), A COMPANY DEDICATED TO THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF AEROSPACE TECHNOLOGIES AND ADVANCED MATERIALS, ANNOUNCES TODAY A SERIES OF INITIATIVES TOWARD THE LAUNCH OF NEXBOARD™ INTO THE GREEN BUILDING MATERIALS MARKET. THESE NEXT STEPS TO MASS COMMERCIALIZATION FOLLOW THE DEVELOPMENT OF A PRECISION CONTROLLED, HIGH-VOLUME MANUFACTURING SYSTEM FOR NEXBOARD COMPOSITE CONSTRUCTION PANELS, A PROPRIETARY PROCESS WHICH DELIVERS QUALITY AND UNIFORMITY WITH LARGE-SCALE PRODUCTION OUTPUT.
|
XERIANT OUTLINES IMMEDIATE INITIATIVES TOWARD NEXBOARD™ COMMERCIALIZATION
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-07-11 08:05:00
| null |
BOCA RATON, FLA., JULY 11, 2023 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT” OR “THE COMPANY”), A COMPANY DEDICATED TO THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF AEROSPACE TECHNOLOGIES AND ADVANCED MATERIALS, ANNOUNCES TODAY THE SUCCESSFUL TESTING OF A PROPRIETARY HIGH-VOLUME PRODUCTION PROCESS FOR ITS ENVIRONMENTALLY-FRIENDLY PATENT-PENDING NEXBOARDTM COMPOSITE CONSTRUCTION PANEL.
|
XERIANT FINALIZES PROPRIETARY MANUFACTURING PROCESS FOR NEXBOARD™ GREEN BUILDING MATERIAL
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-08 08:05:00
| null |
ESTABLISHED U.S. MANUFACTURER OF PLASTIC INDUSTRIAL PRODUCTS TO CONTRIBUTE MATERIAL INTEGRATION EXPERTISE ESTABLISHED U.S. MANUFACTURER OF PLASTIC INDUSTRIAL PRODUCTS TO CONTRIBUTE MATERIAL INTEGRATION EXPERTISE
|
XERIANT PARTNERS WITH TMF CORPORATION FOR NEXBOARD™ TEST PRODUCTION
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-02 08:05:00
| null |
BOCA RATON, FLA., MARCH 02, 2023 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT” OR “THE COMPANY”), A COMPANY DEDICATED TO THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF ADVANCED MATERIALS AND AEROSPACE TECHNOLOGIES, ANNOUNCES AN UPDATE REGARDING THE FUTURE PRODUCTION OF NEXBOARD™, THE FLAME-, WATER-, MOLD- AND INSECT-RESISTANT BUILDING PANEL SET TO REPLACE PRODUCTS SUCH AS DRYWALL, PLYWOOD, OSB, MDF AND MGO BOARD FOR NEW AND RETROFIT CONSTRUCTION.
|
XERIANT EYES U.S. PRODUCTION FOR NEXBOARD™ IN THE NY TRI-STATE AREA
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-08 08:05:00
| null |
BOCA RATON, FLA., SEPT. 08, 2022 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT” OR “THE COMPANY”), A COMPANY DEDICATED TO THE DISCOVERY AND DEVELOPMENT OF ADVANCED MATERIALS AND TECHNOLOGY, ANNOUNCES TODAY THAT IT HAS TRADEMARKED NEX BOARD™ AS THE COMMERCIAL NAME FOR ITS GREEN RETACELL®-BASED WALL PANELS, WHICH CAN BE USED TO REPLACE WALLBOARD PRODUCTS MADE FROM GYPSUM AND WOOD, SUCH AS DRYWALL, PLYWOOD, OSB (ORIENTED STRAND BOARD) AND MDF (MEDIUM-DENSITY FIBERBOARD) FOR NEW AND RETROFIT CONSTRUCTION. XERIANT CONTINUES TO WORK WITH SEVERAL LARGE FIRMS – BOTH DOMESTIC AND INTERNATIONAL – WHICH ARE TESTING THE RETACELL® FIRE RETARDANT TECHNOLOGY IN PLASTICS, WOODS AND TEXTILES FOR VARIOUS APPLICATIONS.
|
XERIANT HAS TRADEMARKED NEXBOARD™ FOR ITS ECO-FRIENDLY RETACELL®-BASED WALL PANELS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-06 08:05:00
| null |
BOCA RATON, FLA., SEPT. 06, 2022 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT” OR “THE COMPANY”), A COMPANY DEDICATED TO THE DISCOVERY AND DEVELOPMENT OF ADVANCED MATERIALS AND TECHNOLOGY, RECENTLY SIGNED ITS FIRST MAJOR LETTER OF INTENT (“LOI”) WITH NEXT NEW CONCEPT (“NNC”) FOR THE PURCHASE OF UP TO $130 MILLION OF XERIANT'S RETACELL®-BASED WALL PANELS, FOR A 35,000-UNIT RESIDENTIAL DEVELOPMENT PROJECT IN AFRICA, ANTICIPATED TO BE COMPLETED WITHIN FIVE YEARS.
|
XERIANT ANNOUNCES FIRST MAJOR LOI FOR RETACELL®-BASED WALL PANELS AND ADDITIONAL BUILDING MATERIALS, WITH POTENTIAL VALUE AT OVER $250 MILLION
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-08-04 09:27:00
| null |
BOCA RATON, FLA., AUG. 04, 2022 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI), AN AEROSPACE COMPANY DEDICATED TO ADVANCED AIR MOBILITY AND ASSOCIATED SPECIALTY CHEMICALS AND MATERIALS, RELEASED A VIDEO CONFERENCE YESTERDAY WITH AN UPDATE ON RECENT COMPANY EVENTS.
|
XERIANT, INC. PRESS CONFERENCE UPDATES AND EXPECTED UPCOMING CATALYSTS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-27 08:05:00
| null |
RECENT POSITIVE DEVELOPMENTS AND UPCOMING MEETINGS PUSH PRESS CONFERENCE INTO JULY RECENT POSITIVE DEVELOPMENTS AND UPCOMING MEETINGS PUSH PRESS CONFERENCE INTO JULY
|
XERIANT PROVIDES UPDATE ON PRESS CONFERENCE AND BUSINESS ACTIVITIES
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-08 08:49:00
| null |
HIGH-STRENGTH, FIRE-RESISTANT PANEL CAN BE MADE WITH RECYCLED CARDBOARD AND PLASTIC HIGH-STRENGTH, FIRE-RESISTANT PANEL CAN BE MADE WITH RECYCLED CARDBOARD AND PLASTIC
|
RETACELL® COMPOSITE PANEL DEVELOPED FOR CONSTRUCTION APPLICATIONS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-26 09:09:00
| null |
KEY APPLICATIONS INCLUDE AIRCRAFT CABINS, AUTOMOTIVE INTERIORS AND HOME FURNISHINGS KEY APPLICATIONS INCLUDE AIRCRAFT CABINS, AUTOMOTIVE INTERIORS AND HOME FURNISHINGS
|
XERIANT COMPLETES CRITICAL PRE-CERTIFICATION TESTING OF RETACELL® FLAME RETARDANT ON SYNTHETIC FABRICS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-24 08:05:00
| null |
BOCA RATON, FLA., MAY 24, 2022 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI), AN AEROSPACE COMPANY DEDICATED TO ADVANCED AIR MOBILITY AND ASSOCIATED SPECIALTY CHEMICALS AND MATERIALS, IS SENDING OUT AN ADVANCE MEDIA ADVISORY TODAY REGARDING THE COMPANY'S PLANNED PRESS CONFERENCE FOR THE PURPOSE OF ANNOUNCING RECENT SIGNIFICANT DEVELOPMENTS. THE PRESS CONFERENCE IS TENTATIVELY SCHEDULED FOR LATE JUNE.
|
XERIANT, INC. ANNOUNCES PRESS CONFERENCE ADVISORY REGARDING RECENT DEVELOPMENTS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-19 08:05:00
| null |
SERVED AS 2ND HIGHEST RANKING MILITARY OFFICIAL IN U.S. DELEGATION TO NATO SERVED AS 2ND HIGHEST RANKING MILITARY OFFICIAL IN U.S. DELEGATION TO NATO
|
AIR FORCE BRIGADIER GENERAL (RET.) BLAINE D.
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-04 08:05:00
| null |
NON-TOXIC RETACELL® POISED TO DISRUPT FLAME RETARDANT INDUSTRY NON-TOXIC RETACELL® POISED TO DISRUPT FLAME RETARDANT INDUSTRY
|
XERIANT TO CAPITALIZE ON EU BAN OF TOXIC FLAME RETARDANTS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-04 08:05:00
| null |
BREAKTHROUGH ECO-FRIENDLY FIRE RETARDANT POTENTIALLY IMPACTS INDUSTRIES VALUED AT OVER $5 TRILLION BREAKTHROUGH ECO-FRIENDLY FIRE RETARDANT POTENTIALLY IMPACTS INDUSTRIES VALUED AT OVER $5 TRILLION
|
XERIANT ENTERS INTO DEFINITIVE AGREEMENT WITH MOVYCHEM ON RETACELL® FIRE RETARDANT TECHNOLOGY
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-03-09 08:05:00
| null |
COL. JOHN “BONES” PARKER (RET.) BRINGS EXPERTISE IN ROTORCRAFT AND FOREIGN MILITARY SALES COL. JOHN “BONES” PARKER (RET.) BRINGS EXPERTISE IN ROTORCRAFT AND FOREIGN MILITARY SALES
|
FORMER BOEING ROTORCRAFT DIRECTOR JOINS XERIANT'S BOARD OF ADVISORS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-12-16 09:05:00
| null |
END-OF-YEAR MESSAGE OUTLINES COMPANY'S STRATEGY FOR FUTURE GROWTH & REVENUE GENERATION END-OF-YEAR MESSAGE OUTLINES COMPANY'S STRATEGY FOR FUTURE GROWTH & REVENUE GENERATION
|
XERIANT PROVIDES UPDATE ON RECENT & UPCOMING ACTIVITIES
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-11-05 08:59:00
| null |
COMPANY ACCOMPLISHES CRUCIAL STEP TO ADVANCE FUTURE PLANS COMPANY ACCOMPLISHES CRUCIAL STEP TO ADVANCE FUTURE PLANS
|
XERIANT CLOSES KEY $6M FINANCING
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-22 09:01:00
| null |
BOCA RATON, FLA., OCT. 22, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT” OR “THE COMPANY”), AN AEROSPACE COMPANY DEDICATED TO ADVANCED AIR MOBILITY, AFFIRMS IT IS WORKING TO COMPLETE A DEFINITIVE MERGER AGREEMENT WITH XTI AIRCRAFT COMPANY, A CLEANTECH OEM AND DEVELOPER OF A LEADING HYBRID-ELECTRIC VTOL AIRCRAFT, THE TRIFAN 600. THE COMPANY'S PREVIOUSLY ANNOUNCED LETTER OF INTENT PROVIDED FOR THE TWO PARTIES TO ENTER INTO THE DEFINITIVE MERGER AGREEMENT WITH A TARGET DATE OF OCTOBER 22, 2021.
|
XERIANT MOVING FORWARD ON XTI MERGER AGREEMENT
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-10-06 11:31:00
| null |
ALFRED RAPETTI, INVESTMENT BANKER AND ENTREPRENEUR, HAS COMPLETED OVER $4 BILLION IN TRANSACTIONS ALFRED RAPETTI, INVESTMENT BANKER AND ENTREPRENEUR, HAS COMPLETED OVER $4 BILLION IN TRANSACTIONS
|
XERIANT ADDS FINANCIAL ARCHITECT TO ADVISORY BOARD
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-27 08:05:00
| null |
ADVANCED AIR MOBILITY TO BE MAJOR FOCUS OF THE 2021 NBAA CONVENTION ADVANCED AIR MOBILITY TO BE MAJOR FOCUS OF THE 2021 NBAA CONVENTION
|
XERIANT TO JOIN XTI AIRCRAFT AT THE NBAA CONVENTION AND OTHER COMPANY NEWS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-22 08:05:00
| null |
BOCA RATON, FLA., SEPT. 22, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTCQB: XERI) (“XERIANT”), AN AEROSPACE COMPANY DEDICATED TO ADVANCED AIR MOBILITY, AND XTI AIRCRAFT COMPANY (“XTI”), AN OEM AND DEVELOPER OF THE TRIFAN 600, A LEADING NEXT-GENERATION HYBRID-ELECTRIC VTOL AIRCRAFT, ANNOUNCED TODAY THAT THEY HAVE EXECUTED A LETTER OF INTENT (THE “LOI”) TO PURSUE A MERGER WHEREBY XERIANT WOULD ACQUIRE 100% OF THE ISSUED AND OUTSTANDING SHARES OF XTI. THE LOI PROVIDES FOR THE PARTIES TO NEGOTIATE AND ENTER INTO A DEFINITIVE MERGER AGREEMENT BY OCTOBER 22, 2021.
|
XERIANT AND XTI AIRCRAFT SIGN LOI TO PURSUE MERGER
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-16 08:05:00
| null |
ROBERT CARULLO WAS INVOLVED WITH 27 NAVY/MARINE AIRCRAFT PROGRAMS INCLUDING THE BELL BOEING V-22 OSPREY TILTROTOR ROBERT CARULLO WAS INVOLVED WITH 27 NAVY/MARINE AIRCRAFT PROGRAMS INCLUDING THE BELL BOEING V-22 OSPREY TILTROTOR
|
XERIANT EXPANDS ADVISORY BOARD WITH FORMER DOD NAVAIR EXECUTIVE
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-08-03 08:05:00
| null |
MOVE FOLLOWS JV WITH CREATOR OF WORLD'S LONGEST-RANGE EVTOL MOVE FOLLOWS JV WITH CREATOR OF WORLD'S LONGEST-RANGE EVTOL
|
XERIANT ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-22 08:05:00
| null |
BOCA RATON, FLA., JUNE 22, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTC PINK: XERI)(“THE COMPANY” OR “XERIANT”), A NEW AEROSPACE TECHNOLOGY AND ADVANCED MATERIALS HOLDING COMPANY, ANNOUNCES THAT IT RECEIVED MEDIA COVERAGE, BOTH DOMESTICALLY AND INTERNATIONALLY, FOR ITS RECENTLY COMPLETED JOINT VENTURE (“JV”) WITH XTI AIRCRAFT COMPANY (“XTI”), A PRIVATELY HELD CLEANTECH AVIATION COMPANY BASED IN ENGLEWOOD, COLORADO.
|
XERIANT'S JV WITH XTI FEATURED IN VARIOUS MEDIA ARTICLES
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-16 08:05:00
| null |
XERIANT POSTS PRESS CONFERENCE AND XTI HIGHLIGHT VIDEOS XERIANT POSTS PRESS CONFERENCE AND XTI HIGHLIGHT VIDEOS
|
THE ROBB REPORT COVERS XERIANT AND XTI AIRCRAFT JOINT VENTURE
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-14 08:54:00
| null |
BOCA RATON, FLA., JUNE 14, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTC PINK: XERI), A NEW AEROSPACE TECHNOLOGY AND ADVANCED MATERIALS HOLDING COMPANY, WILL HOLD AN ONLINE PRESS CONFERENCE, TODAY AT 4:30 P.M. EASTERN TIME WITH XTI AIRCRAFT COMPANY, A PRIVATELY HELD CLEANTECH AVIATION COMPANY BASED IN ENGLEWOOD, COLORADO, TO DETAIL THE JOINT VENTURE BETWEEN THE TWO COMPANIES. THE PRESS CONFERENCE WILL BE HELD AT THE WINGS OVER THE ROCKIES AIR AND SPACE MUSEUM AND WILL BE OPEN TO ALL PRESS, STAKEHOLDERS AND INTERESTED PARTIES, VIA A LIVE STREAMING BROADCAST AT: HTTPS://YOUTU.BE/R0OTR7U1YSW
|
XERIANT / XTI TO HOST LIVE PRESS CONFERENCE TODAY AT 4:30PM EASTERN
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-09 08:05:00
| null |
XTI'S REVOLUTIONARY HYBRID-ELECTRIC TRIFAN 600 AIRCRAFT HAS PRESALES THAT NOW TOP $1.3 BILLION XTI'S REVOLUTIONARY HYBRID-ELECTRIC TRIFAN 600 AIRCRAFT HAS PRESALES THAT NOW TOP $1.3 BILLION
|
XERIANT ANNOUNCES JOINT VENTURE WITH XTI, DEVELOPER OF WORLD'S FASTEST, LONGEST-RANGE COMMERCIAL VTOL
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-06-02 08:05:00
| null |
BOCA RATON, FLA., JUNE 02, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTC PINK: XERI), (“XERIANT” OR “THE COMPANY”), A NEW AEROSPACE TECHNOLOGY AND ADVANCED MATERIALS HOLDING COMPANY ANNOUNCED TODAY THAT IT WILL HOLD A PRESS CONFERENCE ON JUNE 14, 2021 AT 2:30 P.M. MDT, IN DENVER, COLORADO.
|
XERIANT, INC. ANNOUNCES DATE OF UPCOMING PRESS CONFERENCE
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-05-26 12:27:00
| null |
BOCA RATON, FLA., MAY 26, 2021 (GLOBE NEWSWIRE) -- XERIANT, INC. (OTC PINK: XERI), A NEW AEROSPACE TECHNOLOGY AND ADVANCED MATERIALS HOLDING COMPANY, IS SENDING OUT AN ADVANCE PRESS ADVISORY TODAY DESCRIBING THE COMPANY'S PLAN TO HOLD A PRESS CONFERENCE FOR THE PURPOSE OF ANNOUNCING RECENT SIGNIFICANT DEVELOPMENTS. THE PRESS CONFERENCE IS TENTATIVELY SCHEDULED FOR MID-JUNE.
|
XERIANT, INC. ANNOUNCES PRESS CONFERENCE ADVISORY REGARDING RECENT DEVELOPMENTS
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-27 08:05:00
| null |
COMPANY'S NEW YOUTUBE CHANNEL “HEATS UP” BY HIGHLIGHTING RETACELL'S REMARKABLE PROPERTIES COMPANY'S NEW YOUTUBE CHANNEL “HEATS UP” BY HIGHLIGHTING RETACELL'S REMARKABLE PROPERTIES
|
XERIANT PUBLISHES VIDEOS OF MOVYCHEM'S “GREEN” FIRE PROTECTION ABILITIES
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-22 08:05:00
| null |
COMPANY CELEBRATES EARTH DAY BY ANNOUNCING THAT IT'S ENTERING PRODUCT TESTING PHASE WITH GLOBAL INDUSTRY LEADERS COMPANY CELEBRATES EARTH DAY BY ANNOUNCING THAT IT'S ENTERING PRODUCT TESTING PHASE WITH GLOBAL INDUSTRY LEADERS
|
XERIANT PROVIDES MOVYCHEM COMMERCIALIZATION UPDATE
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-04-01 08:05:00
| null |
JV WITH ADVANCED MATERIAL MANUFACTURER WILL IMMEDIATELY TARGET POTENTIAL AEROSPACE APPLICATIONS, WITH ECO-FRIENDLY FIRE PROTECTION TECHNOLOGY, AND THEN EXPLORE ADDITIONAL MARKETS JV WITH ADVANCED MATERIAL MANUFACTURER WILL IMMEDIATELY TARGET POTENTIAL AEROSPACE APPLICATIONS, WITH ECO-FRIENDLY FIRE PROTECTION TECHNOLOGY, AND THEN EXPLORE ADDITIONAL MARKETS
|
XERIANT SIGNS JOINT VENTURE WITH MOVYCHEM
|
XERI
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.